We aim to foster a culture of entrepreneurship, innovation and success among engineers in the UK, creating economic growth and societal impact. At the heart of how we do this are the Hub Members, the promising entrepreneurs who we support through our programmes, and our Hub Mentors, the business leaders who volunteer their expertise and time to help the Hub Members succeed.
From manufacturing to medtech, our Hub Membership is made up of some of the UK’s most innovative entrepreneurs. But don’t just take our word for it: read more about our Hub Members to see how they are, without exaggeration, changing the world.
Charco NeurotechLtd has developed the CUE1, a small, non-invasive, wearable therapeutic device for people with Parkinson’s disease. Worn on the sternum, the device delivers two validated neuromodulation therapies at the same time: focused vibrotactile stimulation and ‘cueing’. These improve motor performance and alleviate numerous symptoms, for example countering ‘freezing of gait’ (when people feel their feet are stuck to the ground).
The CUE1’s focused stimulation works with the body’s sensory system to help improve the speed and fluidity of an individual’s movement. Cueing uses regular or rhythmic stimuli to assist a person with Parkinson’s to start and continue movements like walking. Patients who have benefitted from the CUE1 say that their motions become smoother and better coordinated when wearing the device.
Everyone’s Parkinson’s is different, so an accompanying Bluetooth-enabled app (the CUE app) allows an individual to fine-tune the device’s vibration settings. It also provides a symptom tracker plus interactive games to record progress and movement.
Soo-Min (Lucy) Jung is the co-founder and CEO at Charco Neurotech. Lucy joined the Shott Scale Up Accelerator in 2022 and says, “As Charco grows, I would like to enhance my leadership skills in several key areas, including strategic negotiations and dealmaking. The mentorship will also be an important element in my professional development – I will benefit both from the mentor’s advice and their expertise.”
At the end of 2021, Charco raised £7.4 million in a seed investment round. The company will use this to expand its team and continue the release of the CUE1. The funding will also ensure that the production of the device is fully scalable and the manufacturing quality is consistent. The backers of Charco believe that the CUE1 has the ability to greatly enhance the quality of life for people diagnosed with Parkinson’s worldwide.
Porotech has created a new class of semiconductor material: porous GaN, a composite of solid GaN and air. The company’s breakthroughs enable nanoscopic holes to be made in the semiconductor, resulting in a wide range of optical, mechanical, thermal, and electrical properties. The company is also delivering monochrome and full-colour micro-LED products to exceptionally high specifications.
Before this innovation, the manufacture of full-colour micro-LED displays was complicated and commercially prohibitive. Several material systems needed to be combined to develop a finished product. Porotech’s innovative process allows monochrome and full-colour displays to be placed on a single indium gallium nitride material system at mass scale, with the luminosity, efficiency and resolution needed for high-quality image projection against bright backgrounds.
Now, all three light-emitting elements can be produced using a single toolchain. Porotech’s technology offers a brand new material platform for semiconductor devices to be built on. This will be relevant for emerging markets such as micro-LED displays, metasurfaces, sensors, lasers, and quantum light sources.
Dr Yingjun Liu is the co-founder and CTO of Porotech Ltd, and joined the Shott Scale Up Accelerator in 2022. He says, “As I am responsible for setting the technology plan and managing growing teams, I want to develop a unique blend of management and technical skills for a high-growth business. Being able to exchange ideas with future industrial leaders and learn from leading entrepreneurs will help me contribute even more to our company’s global business and technology progress.”
Porotech recently secured £14.5 million in Series A funding. This investment will help the company to speed up its production of micro-LED products and rapidly scale up. Micro-LED displays will play an important part in subsequent generations of TVs, wearables, smartphones, and AR glasses.
Surfactants, used to decrease surface or interfacial tensions, have multiple uses in the chemical industry. Their industrial applications include household detergents, cosmetics, and agriculture. Holiferm Ltd, a Manchester-based company, is looking to move away from non-fossil-based chemical surfactants by developing and supplying sustainable, fermentation-derived ingredients for industrial and consumer products.
Holiferm has developed commercially viable, continuous manufacturing processes for biosurfactants and lipids that are able to deliver green products to the mass market at volume, and at competitive prices. The company’s patented integrated gravity separation and fermentation technology increases fermentation process productivity fourfold and reduces biosurfactant production costs by more than 50%.
Vicky De Groof joined Holiferm as a fermentation engineer. Within a year she had become the company’s Chief Technology Officer, responsible for a team of 10 people. Vicky then joined the Shott Scale Up Accelerator programme in 2022, and says, “I hope the networking opportunities and workshops will allow me to meet others, create new ideas, widen my perspectives, build my business confidence and lead to serendipitous findings.”
Holiferm is aiming to persuade the £27 billion surfactant market to move away from petroleum-based chemicals to biobased, sustainable alternatives. In 2021, the company started the year with a team of 10 and a pilot plant. By the end of that year, it had raised over £7 million of investment, increased the team to 20 people, and started to build a commercial plant.
Now, it is developing and refining new processes, doubling the team count again and generating a clear product pipeline. Holiferm’s fermentation technology will enable it to produce other types of biosurfactants and fermentation-derived chemicals that will help transform the chemical industry into a more sustainable one.
There are approximately 50 pantograph (an apparatus mounted on the roof of an electric train to collect power through contact with an overhead line) related incidents in the UK each year. These cause cancellations of passenger services, damage infrastructure, reduce safety and reliability of electrified train operation and have huge financial implications (tens of millions of pounds per incident) for both train operating companies and infrastructure managers such as Network Rail.
A lack of real-time information about pantograph operation and being unable to regularly inspect the infrastructure to inform data-driven decisions currently costs Network Rail around £530 million per annum.
Sentech Analytics Ltd has developed a new ‘smart-pantograph’ system: a multi-parameter, patented and field-evaluated optical fibre-based sensor system integrated with video information, to inform better data-driven maintenance solutions. This system allows users to create comprehensive inspection reports (required by the regulatory bodies) and reduce maintenance costs by providing real-time insight on the status of infrastructure and railway pantographs, preventing costly incidents while reducing maintenance and service outages.
Recent work with Network Rail on the Great Western Electrification programme illustrated this, and the smart pantograph now facilitates faster, more environmentally friendly passenger journeys between Bristol and Cardiff.
The company’s plan moving forward is to get detailed understanding of the challenges faced by the main stakeholders (within the UK and EU), to secure a pilot project and establish appropriate business models for two different market segments: train operating companies and infrastructure managers.
“In this very short period of time, the training provided by the Royal Academy of Engineering has been very important for my personal development as well as a great guidance on how to establish the company. In addition to that, having regular conversations with staff and my coach has been very helpful to get answers to a number of dilemmas.”
When a manufacturer, for example a car maker, wants a new component made, it will go to a supplier with its specifications. To make this new item, the supplier needs material multi-axial property data to predict its materials’ response in the manufacturing process. Existing testing methods cannot supply such data across all possible temperature and stress states.
To solve this issue, Dr Zhutao Shao and his colleagues from Imperial College London have developed and patented the world’s first high-temperature multi-axial material testing system. This patented testing process involves stretching a piece of material from multiple directions and under different service conditions until it fractures. Customers are then given the data and can use it to optimise their material’s structure.
Most existing systems use room temperature for testing and some may go up to 300° to 500°C. Dr Shao’s innovation can go over 1,000°C when needed. This option is important when judging how a material will behave under various stress states during the hot stamping manufacturing process. His multi-axial testing also undertakes fatigue, tension and compression testing of materials within a wide range of temperatures. The suite of checks are labelled ‘hot multi-axial tests’.
Multi-X Solutions already collaborates with car component suppliers for lightweight structural design and production of vehicles and will start trial sales in 2020. The company currently has one service and two products open to the transportation industry. Multi-X Solutions also has a materials database that will be added to as the company conducts tests on more engineering materials and structures.
The market that Multi-X are working in stands at £850 million worldwide and is rapidly expanding. The company is now looking to further develop and standardise the cost-effective testing methods for the data-driven advanced manufacturing industry.
2018 Awarded Engineering and Physical Sciences Research Council Impact Acceleration Account funding
2018 Awarded title of the Most Valuable Project in Tencent Auto Open Platform Competition
2019 Dr Zhutao Shao was awarded an Enterprise Fellowship
2020 Accepted onto Imperial Techcelerate Programme
Unmanned Life’s software-as-a-service platform integrates different types of drones and robots to work together as autonomous fleets. The company uses AI to automatically deploy and manage UAVs and ground vehicles, both indoors and outdoors. These collaborative autonomous workforces can be used for a variety of business uses including surveillance and security, public safety, emergency response, warehousing, logistics, shipping and inventory counts.
Unmanned Life’s Autonomy-as-a-Service platform works over the cloud, with or without GPS, and communicates via radio, Wi-Fi, 4G or 5G. It can integrate swarms of different types of robotic devices to work together and its services have potential for the Industry 4.0 and Smart City applications.
Wasif Mehdi, is the Chief Operating Officer at Unmanned Life responsible for company operations and portfolio delivery. He also fills the role of Product Lead, jointly with the CTO and CEO. Wasif joined the Shott Scale Up Accelerator programme in 2022. He says, “Networking with my peers will enable a cross-pollination of ideas, strategies and approaches for us. I see the accelerator as a critical source of knowledge, experience and skills that will feed into our business’s day-to-day operations. This will be especially relevant across our teams, processes and tools, and help smooth our scale up journey.”
Unmanned Life has already succeeded in getting significant investment and establishing working partnerships. The company is now looking to secure recurring commercial revenue contracts — a key milestone to achieve in preparation for a Series A funding round. It will then be able to fully exploit its position as the world’s leading provider of a cloud-based, software-controlled, fully autonomous drone and robot service platform.
Recycleye Ltd has created the world’s largest visual AI dataset of waste materials, working in collaboration with academics from leading European universities. Using this knowledge, the company has developed Recycleye Vision, a database with over 3 million labelled images classifying waste. This system combines AI, smart analytics and low-cost cameras to identify refuse in real time. It can further refine identification by weight and brand detection and is already being used in large materials recovery facilities (MRFs) in England, Northern Ireland, France and Italy.
Recycleye Robotics encompasses a robotic picking system in tandem with the Recycleye Vision database to physically pick up the recyclable waste at an MRF and place it into containers. The robot can pick 55 items a minute and is both more consistently efficient and accurate than human pickers. By applying machine learning, the system is able to detect differences between items such as food and non-food-grade plastics. As a result, the increased accuracy of the process boosts the resale value of the output bales of an MRF’s recyclables by as much as fivefold.
Peter Hedley is the co-founder and CTO at Recycleye, and joined the Shott Scale Up Accelerator programme in 2022. He says, “Our company has expanded so quickly that I am now the manager of other managers! I feel the accelerator scheme will give me the support to improve our planning, culture and technical strategy. The programme will also give me access to a network of other senior SME people who will share valuable knowledge at a critical stage of our growing business.”
Recycleye’s potential has already been recognised and it has raised around £5 million to date. The company will use this funding to scale up and increase the accuracy and capabilities of its machine learning and robotics technology. It will also look to expand its product line and find more European partners.
Material Evolution Ltd is using machine learning algorithms and patented geopolymer technology to turn waste into new materials. The company’s first success has been to use its pioneering chemical and manufacturing processes to produce a cement replacement made from 96% industrial waste.
The main carbon emitter in concrete is cement. By developing previously unused waste streams, such as slag from the steel industry, Material Evolution has been able to reduce CO2 emissions in its cement by 85%. The company’s machine learning algorithms ensure material consistency and repeatability in every batch.
Dr Elizabeth (Liz) Gilligan is a co-founder and the CEO of Material Evolution. Liz provides the technical direction for the company, as well as fundraising and selling. In 2022, she joined the Shott Scale Up Accelerator programme and says, “This will hone my leadership skills for running our technical and non-technical teams. I plan to use the accelerator to develop more contacts and establish the best ways to inform people about the company and its products.”
Material Evolution’s potential has already been recognised. Towards the close of 2021, it raised £2.5 million in seed investment and grants. The company intends to use this to hire more team members, develop more products and set up batch production facilities. It ambitions are to work on new waste streams, achieve a production capacity of 100,000 tonnes, and further evolve its production algorithms. This will help the company achieve its aim: to help rapidly and radically decarbonise the UK’s foundation industries by improving their energy and resource efficiencies.
Cell and gene therapies have proven to be effective methods of treatment for diseases such as Parkinson’s disease and a range of cancers. However, there are two main challenges hindering the use and accessibility of these therapies. The first is that development timelines can be slow, due to time spent on resource-intensive process redesigns. The second is that manufacturing costs are currently high, due to expensive reagents, the necessity of clean room facilities and high batch failure rates.
MicrofluidX Ltd is tackling the problems of process control, scalability, and high costs associated with cell bioprocessing, particularly for autologous cell and gene therapy. Its automated closed technology enables scientists to speedily carry out process development by running dozens of cell culture conditions in parallel, with extreme process control. MicrofluidX’s strategy then facilitates scale up of the optimal condition to several billion cells for manufacturing at a fraction of current costs, while maintaining the same process development cell environment, thus avoiding expensive process redesigns.
Dr James Kusena is Vice President of Bioprocessing and Applications at MicrofluidX. James joined the Shott Scale Up Accelerator programme in 2022. He says, “There are several areas of expertise that I would like to develop including: creative and strategic thinking, project management and effective decision-making. These would allow me to enhance my leadership skills for both projects and partnerships.”
MicrofluidX is now looking to further develop its microfluidics-based cell and gene therapy process development and manufacturing platforms. The company will do this by disseminating a range of prototypes to partners in order to gain further external validation. It will also finalise the research and development of its chip and cassette designs, ready for manufacturing. This will permit MicrofluidX to grow its network and close its Series A funding.
What makes us different is the Academy’s Fellows and our wider Mentor network – an unrivalled community of the UK’s most successful industry leaders, technology experts and entrepreneurs. Find out more about our Mentors and their areas of expertise.
Brewster Barclay has been selling, marketing and product managing for more than 40 years in a wide variety of high technology industries including printed circuit boards, both manufacturing processes and capital equipment, 3D circuit boards, online advertising, optical sensors, military chip packaging, radar tubes and software engineering services. Brewster has worked at Zuhlke Engineering, e2v technologies, Clicktream Technologies, Orbotech and PCK Technology Kollmorgen.
The experience of launching new products and almost six years running an internet advertising startup led to Brewster giving back in the form of mentoring early stage and growth startups. He identified a massive gap in business development, sales support and strategy that angels, accelerators and VCs give to startups. He has focused solely on sharing his experiences in business development sales, sales techniques and the practicalities of day to day sales and lead generation.
He has mentored at the Royal Academy of Engineering for the past seven years as well as for Accelerate Cambridge, Seraphim Space Capital and many other groups.
Vida is a behavioural change coach with over seven years’ experience helping people think differently and positively change lives. She helps people to build connection and balance in order to create a sustainable future for themselves, others and the world. Vida does this as a speaker, trainer and coach, focusing on wellbeing, self-care, belief change, and motivation.
Having worked in prisons and schools as well as the public sector with non-clinical NHS staff and private sector for companies such Telefónica and Wavin, she has a unique insight to share.
Professor Alison Noble is the Technikos Professor of Biomedical Engineering, in the Department of Engineering Science at the University of Oxford, and Associate Head of MPLS Division. She is a Fellow of the Royal Society (2017), the Royal Academy of Engineering (2008) and the President of the Medical Image Computing and Computer Assisted Interventions (MICCAI) Society, the international society in biomedical image analysis.
Alison’s research interests are in computer analysis of clinical and biological images and the development and translation into clinical practice of novel methodologies that provide new diagnostic and therapeutic image based biomarkers and software tools for image-based quantification and decision-making. Her research group works in close collaboration with clinicians and industry players. She is also a Founder and the Chief Technology Officer of a university spin-out company that is commercialising research from her laboratory (Intelligent Ultrasound Ltd).
She returned to Oxford as a University Lecturer in 1995 to set up a biomedical image analysis group. Biomedical image analysis has since grown to be the largest biomedical engineering activity in Oxford.
Alison has played a leading role in setting up the biomedical engineering undergraduate and postgraduate biomedical engineering teaching and training (MSc and CDT) programmes at Oxford over the last decade. She is a member of both the Oxford University’s Research and Education Committees (from Oct 2013), and has served or currently serves on a number of committees of the Royal Academy of Engineering and other national organisations as well as numerous research funding agency panels.
Andy’s career in industry has involved co-founding over a dozen spin-outs and start-ups, three of which floated on stock markets. Virata floated on NASDAQ and at its peak had a market capitalisation of $5 billion.
His most prominent successes have come through RealVNC, which won the prestigious MacRobert Award in 2013, and Ubisense plc. Collectively, these two organisations have received five Queen’s Awards for Enterprise.
In academia, Andy heads the University of Cambridge’s Computer Laboratory and is an Honorary Fellow of Trinity Hall and Corpus Christi College. Elsewhere, he served as President of the IET between 2012 and 2013, and in 2007 received a CBE for services to the computer industry.
Andy is co-founder and Chairman of pioneering remote access software developers RealVNC and is also Professor of Computer Technology at the University of Cambridge. He was elected a Fellow of the Royal Academy of Engineering in 1996.
“My own career experiences have demonstrated just how important it is that the bridges between academia and industry are present and robust, and also what can be achieved when the relationship works to its potential. The Enterprise Hub offers an invaluable opportunity for exceptional academics to work with experienced industry figures and bring truly exciting new technology businesses to fruition.”
Bill is a leading scientist worldwide in the field of Medical Materials. His major research contributions have been recognised by numerous international awards, medals and memberships.
He has been the Professor of Medical Materials at the University of Cambridge; served as Director of Cambridge Pfizer Institute for Pharmaceutical Materials Science; Cambridge Director of CMI Interdisciplinary Research Cluster in Biomaterials and Tissue Engineering and Director of University of London Interdisciplinary Research Centre (IRC) in Biomedical Materials. He has been Head of Department, Dean, and Governor at Queen Mary University of London.
He has been the editor of the Journal of The Royal Society: Interface, the Journal of Materials Science: Materials in Medicine, the Journal of Materials Science, and of the Journal of Materials Science Letters.
Bill is Emeritus Professor of Medical Materials in the University of Cambridge. He is internationally recognised for his pioneering research contributions to biomaterials for medical devices, with awards including the Royal Academy of Engineering Prince Philip Gold Medal; the Royal Society Armourers and Brasiers Company Medal; the Kelvin Medal; the European Society for Biomaterials George Winter Award; the Japanese Society for Biomaterials Medal; the Institute of Materials Griffiths Medal and Chapman Medal; the UK Society for Biomaterials President's Prize; the Acta Metallurgica H.H. Holloman Award and the International Union for Physical Sciences and Engineering in Medicine Award of Merit.
Professor Bonfield's exceptional interdisciplinary contribution has been recognised by his election to all three UK National Academies as a Fellow of the Royal Society (FRS), a Fellow of the Royal Academy of Engineering (FREng) and a Fellow of the Academy of Medical Sciences (FMedSci).
Matthew is a technology specialist with more than 26 years of experience in software engineering, consulting, product development, and startups. Matthew joined the London office of BCG Digital Ventures (DV) in January 2016.
As Partner and Vice President, Engineering, Matthew oversees technology and engineering across all ventures at DV London. As the current speaker for DV's engineering executive committee, Matthew also takes an active role in coordinating the engineering cohort across DV's centres around the world.
Over the last five years, Matthew has been involved in a wide variety of ventures, starting as the CTO of Coup in 2016. He has moved on to director, advisory, and other senior leadership roles across diverse sectors including industrial goods, finance and insurance tech, mobility, resources, e-commerce, and private equity. During his time at DV, Matthew has been involved in the ideation, incubation, and launch of more than 20 internal or publicly launched client ventures.
Before joining DV, Matthew delivered highly complex technology systems in the telecommunications, financial services and payments sectors. Working with startups, product teams, and consulting organisations from Australia, Asia, and Europe, Matthew has helped to build everything from network analysers and flight simulators, through to high-performance mission-critical EFT payment transaction switches, online and mobile banking, and shared mobility platforms.
Matthew blogs on Medium and is always happy to chat about anything to do with technology and the future.
Professor Nicholas Medcalf FREng has worked for Innovate UK, part of UK Research and Innovation, since 2017. He is the Deputy Challenge Director for the Medicines Manufacturing Challenge in the Industrial Strategy Challenge Fund team. The work involves building business cases for government investment in capital and R&D projects to boost UK health and wealth and delivery of funded programmes.
Nick retains a Visiting Professor role at Loughborough University where he was Professor of Regenerative Medicine Manufacture and Director of the Engineering and Physical Sciences Research Council (EPSRC) Centre for Innovative Manufacturing in Regenerative Medicine under an EPSRC Fellowship.
Nick has experience in regenerative medicine development building on a career in industry as a chemist and chemical engineer. Nick is a chartered chemist and a chartered chemical engineer, and he has spent a significant amount of his career working within Smith & Nephew. Nick also has experience in quality assurance, process design, regulatory affairs and economic analysis.
His specialties include: project cost projections and cost control; advice to grant funding bodies; set up and management of cleanroom facilities and pilot plants; application of healthcare regulations to new medical product development; project planning and control; and the construction of efficient quality management systems for medical research programmes.
He was made Fellow of the Royal Academy of Engineering in 2011.
Rupert is a seasoned startup entrepreneur and CEO. He has founded several technology companies and been involved in three successful exits.
Most recently he was CEO of UltraSoC, which he took from struggling academic spinout to success, selling to Siemens in summer 2020 (a deal done wholly over Zoom over lockdown).
Before UltraSoC, he was Vice-President of Strategic Marketing at Mindspeed following that company’s acquisition of Picochip (now Intel), where he was Chief Marketing Officer. His CV also includes spells at first:telecom (on track for IPO on LSE before acquisition by Atlantic Telecom), Pond Ventures (early-stage deep-tech VC), Arthur D Little, and Analog Devices where he played a key role in the development and mass-market adoption of DSL. His first startup at age 22 was based on his undergraduate thesis.
Rupert has worked in the UK, US and Europe. He has a degree and postgraduate diploma in electronic engineering from the University of Hull and an MBA from IESE. He is a Chartered Engineer (CEng) and a Fellow of the Institution of Engineering and Technology (FIET). He is also a Fellow of the Royal Society of Arts (FRSA).
Farnaz is a consultant at Deloitte’s London office. Prior to that, was a consultant based in McKinsey. Specialising in life sciences – with nearly 11 years of combined research and consulting experience – Farnaz has management consulting experience leading corporate and business unit strategy; digital transformation; big data strategy; operating model transformation; organisational model redesign; capability design; productivity improvement; business process re-engineering; and business case development for clients. Farnaz primarily focuses on clients in healthcare life sciences, namely the pharmaceutical sector.
Farnaz has additional experience serving clients in other industries, including medical devices, retail, financial services, consumer packaged goods, non-profit, and the international public sector. Her strong soft skills and work experience at a global level has enabled her to engage with teams and clients at all levels.
Farnaz is an active volunteer at the United Nations, developing partnership and communications strategy for the community hospital construction and operations. Farnaz is involved in the UK startup space as a mentor at Accelerate Cambridge, Oxford Foundry and now the Enterprise Hub, mentoring entrepreneurs at various stages in their business development journey.